LamiVUDine 150 mg / zidovudine 300 mg Oral Tablet
RxNorm 200082
Concept Hierarchy & Relationship Mapping
RxNorm Concept Unique Identifier (RxCUI) 200082 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: lamiVUDine 150 mg / zidovudine 300 mg Oral Tablet.
The following semantic concepts and normalized strings are associated with this clinical entity:
This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.
Semantic Clinical Drug (SCD):
Lamivudine 150 mg / zidovudine 300 mg Oral Tablet
(Atom ID: 12324627)
Synonym (SY):
3TC 150 mg / AZT 300 mg Oral Tablet
(Atom ID: 3856696)
Prescribable Name (PSN):
LamiVUDine 150 mg / zidovudine 300 mg Oral Tablet
(Atom ID: 6361055)
Tall Man Lettering Synonym (TMSY):
LamiVUDine 150 mg / zidovudine 300 mg Oral Tablet
(Atom ID: 12383785)
Designated preferred name (PT):
Lamivudine 150 mg and zidovudine 300 mg oral tablet
(Atom ID: 9251440)
Full form of descriptor (FN):
Product containing precisely lamivudine 150 mg and zidovudine 300 mg/1 each conventional release oral tablet (clinical drug)
(Atom ID: 10314075)
Patient Education
Lamivudine and Zidovudine
The combination of lamivudine and zidovudine is used along with other medications to treat human immunodeficiency virus (HIV) infection. Lamivudine and zidovudine are in a class of medications called nucleoside reverse transcriptase inhibitors (NRTIs). They work by decreasing the amount of HIV in the blood. Although the combination of lamivudine and zidovudine does not cure HIV, it may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer. Taking these medications along with practicing safer sex and making other life-style changes may decrease the risk of transmitting (spreading) the HIV virus to other people.
[Learn More]
HIV/AIDS Medicines
What is HIV/AIDS?
HIV stands for human immunodeficiency virus. It harms your immune system by destroying CD4 cells. These are a type of white blood cells that fight infection. The loss of these cells makes it hard for your body to fight off infections and certain HIV-related cancers.
Without treatment, HIV can gradually destroy the immune system and advance to AIDS. AIDS stands for acquired immunodeficiency syndrome. It is the final stage of infection with HIV. Not everyone with HIV develops AIDS.
What is antiretroviral therapy (ART)?
The treatment of HIV/AIDS with medicines is called antiretroviral therapy (ART). It is recommended for everyone who has HIV. The medicines do not cure HIV infection, but they do make it a manageable chronic condition. They also reduce the risk of spreading the virus to others.
How do HIV/AIDS medicines work?
HIV/AIDS medicines reduce the amount of HIV (viral load) in your body, which helps by
- Giving your immune system a chance to recover. Even though there is still some HIV in your body, your immune system should be strong enough to fight off infections and certain HIV-related cancers.
- Reducing the risk that you will spread HIV to others
What are the types of HIV/AIDS medicines?
There are several different types of HIV/AIDS medicines. Some work by blocking or changing enzymes that HIV needs to make copies of itself. This prevents HIV from copying itself, which reduces the amount of HIV in the body. Several medicines do this:
- Nucleoside reverse transcriptase inhibitors (NRTIs) block an enzyme called reverse transcriptase
- Non-nucleoside reverse transcriptase inhibitors (NNRTIs) bind to and later change reverse transcriptase
- Integrase inhibitors block an enzyme called integrase
- Protease inhibitors (PIs) block an enzyme called protease
Some HIV/AIDS medicines interfere with HIV's ability to infect CD4 immune system cells:
- Fusion inhibitors block HIV from entering the cells
- CCR5 antagonists and post-attachment inhibitors block different molecules on the CD4 cells. To infect a cell, HIV has to bind to two types of molecules on the cell's surface. Blocking either of these molecules prevents HIV from entering the cells.
- Attachment inhibitors bind to a specific protein on the outer surface of HIV. This prevents HIV from entering the cell.
In some cases, people take more than one medicine:
- Pharmacokinetic enhancers boost the effectiveness of certain HIV/AIDS medicines. A pharmacokinetic enhancer slows the breakdown of the other medicine. This allows that medicine to stay in the body longer at a higher concentration.
- Multidrug combinations include a combination of two or more different HIV/AIDS medicines
When do I need to start taking HIV/AIDS medicines?
It's important to start taking HIV/AIDS medicines as soon as possible after your diagnosis, especially if you
- Are pregnant
- Have AIDS
- Have certain HIV-related illnesses and infections
- Have an early HIV infection (the first 6 months after infection with HIV)
What else do I need to know about taking HIV/AIDS medicines?
It's important to take your medicines every day, according to the instructions from your health care provider. If you miss doses or don't follow a regular schedule, your treatment may not work, and the HIV virus may become resistant to the medicines.
HIV medicines can cause side effects. Most of these side effects are manageable, but a few can be serious. Tell your health care provider about any side effects that you are having. Don't stop taking your medicine without first talking to your provider. He or she may give you tips on how to deal with the side effects. In some cases, your provider may decide to change your medicines.
What are HIV PrEP and PEP medicines?
HIV medicines are not just used for treatment. Some people take them to prevent HIV. PrEP (pre-exposure prophylaxis) is for people who don't already have HIV but are at very high risk of getting it. PEP (post-exposure prophylaxis) is for people who have possibly been exposed to HIV.
NIH: Office of AIDS Research
[Learn More]
* Please review the disclaimer below.
